Literature DB >> 22235959

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Michael Rader, Carsten Goessl, Ze Cong.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22235959     DOI: 10.18553/jmcp.2012.18.1.74

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


× No keyword cloud information.
  1 in total

Review 1.  Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases.

Authors:  Kaitlin Koo; Kinsey Lam; Nicole Mittmann; Andre Konski; Kristopher Dennis; Liang Zeng; Henry Lam; Edward Chow
Journal:  Support Care Cancer       Date:  2013-03-22       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.